Find a
  WATCHMAN  
Implanter

THE RECENT CMS DECISION MAY BENEFIT PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION (NVAF) WHO HAVE A REASON TO SEEK AN ALTERNATIVE TO OACS


  • The Centers for Medicare and Medicaid Services (CMS) issued a final decision memo supporting the national coverage determination (NCD) for percutaneous LAAC therapy (NCD 20.34) when specific conditions are met1
  • This major milestone provides appropriate and uniform coverage for Medicare beneficiaries that is largely consistent with the WATCHMAN FDA label
  • Our GuidePoint Reimbursement Resources have been updated to reflect the positive NCD to assist physicians and hospitals in seeking coverage and payment consideration of WATCHMAN implants on a case-by-case basis from private payers and provide additional information on the NCD

QUESTIONS?


For questions related to WATCHMAN reimbursement, please call

1-800-CARDIAC 

 

Follow Us: Twitter LinkedIn YouTube Google+
Top